Royal Bank of Canada’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-578
| Closed | -$128K | – | 7169 |
|
|
2025
Q4 | $128K | Sell |
578
-51,803
| -99% | -$8.37M | ﹤0.01% | 5062 |
|
|
2025
Q3 | $5.02M | Buy |
52,381
+21,114
| +68% | +$1.35M | ﹤0.01% | 2676 |
|
|
2025
Q2 | $1.52M | Buy |
+31,267
| New | +$751K | ﹤0.01% | 3531 |
|
|
2024
Q3 | – | Sell |
-67
| Closed | -$1K | – | 6901 |
|
|
2024
Q2 | $1K | Buy |
+67
| New | +$917 | ﹤0.01% | 6793 |
|
|
2024
Q1 | – | Sell |
-12
| Closed | – | – | 7051 |
|
|
2023
Q4 | $0 | Sell |
12
-311
| -96% | -$5K | ﹤0.01% | 7151 |
|
|
2023
Q3 | $6K | Buy |
323
+161
| +99% | +$3.16K | ﹤0.01% | 6562 |
|
|
2023
Q2 | $4K | Sell |
162
-926
| -85% | -$21.8K | ﹤0.01% | 6720 |
|
|
2023
Q1 | $27K | Buy |
1,088
+1,087
| +108,700% | +$30.8K | ﹤0.01% | 5906 |
|
|
2022
Q4 | $0 | Buy |
+1
| New | +$12 | ﹤0.01% | 7261 |
|
|
2021
Q3 | – | Sell |
-99
| Closed | -$4K | – | 7644 |
|
|
2021
Q2 | $4K | Sell |
99
-93
| -48% | -$3.94K | ﹤0.01% | 7110 |
|
|
2021
Q1 | $10K | Buy |
192
+47
| +32% | +$2.32K | ﹤0.01% | 6800 |
|
|
2020
Q4 | $6K | Buy |
+145
| New | +$7.21K | ﹤0.01% | 6575 |
|
|
2020
Q3 | – | Sell |
-31
| Closed | -$2.19K | – | 6646 |
|
|
2020
Q2 | $2K | Buy |
+31
| New | +$2.01K | ﹤0.01% | 6270 |
|
|
2019
Q4 | – | Sell |
-24
| Closed | -$1K | – | 6840 |
|
|
2019
Q3 | $1K | Buy |
+24
| New | +$807 | ﹤0.01% | 6410 |
|
|
2018
Q4 | – | Sell |
-2
| Closed | – | – | 6773 |
|
|
2018
Q3 | $0 | Buy |
+2
| New | +$176 | ﹤0.01% | 6727 |
|
|
2017
Q2 | – | Sell |
-25
| Closed | -$4K | – | 6572 |
|
|
2017
Q1 | $4K | Sell |
25
-13
| -34% | -$2.28K | ﹤0.01% | 6269 |
|
|
2016
Q4 | $8K | Buy |
+38
| New | +$7.9K | ﹤0.01% | 6151 |
|
|
2015
Q4 | – | Sell |
-15
| Closed | -$4K | – | 6642 |
|
|
2015
Q3 | $4K | Sell |
15
-1
| -6% | -$286 | ﹤0.01% | 6213 |
|
|
2015
Q2 | $5K | Buy |
+16
| New | +$4.92K | ﹤0.01% | 6235 |
|
Royal Bank of Canada's CDTX Position: Q1 2026 in Review
Royal Bank of Canada sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 578 shares — an estimated $128K sold.
Royal Bank of Canada first reported a position in CDTX in Q2 2015 and held it in 19 quarters. The position peaked at $5.02M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Royal Bank of Canada reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Royal Bank of Canada sold 578 Cidara Therapeutics shares in Q1 2026, an estimated $128K.
- Royal Bank of Canada first reported a position in Cidara Therapeutics in Q2 2015 and held it in 19 quarters.
- Royal Bank of Canada's Cidara Therapeutics position peaked at $5.02M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.